Januvia is known as a dipeptidyl peptidase-4 (DPP-4) inhibitor which is an approved treatment in conjunction with proper diet and exercise for those diagnosed with Type-2 diabetes. The drug was first introduced to the market by Merck in October of 2006 and shortly thereafter was linked to pancreatic disease such as cancer.
The main side effect associated with Januvia is chronic pancreatitis which in some patients manifested into pancreatic cancer, one of the fourth most common causes of cancer-related death in the United States. Within only three years of its introduction to the market, Januvia was linked to an increased number cases of pancreatitis, or inflammation of the pancreas. Since then numerous studies have shown the link between the drug and pancreatitis and cancer.
The FDA recently issued a drug safety communication and they are currently evaluating the alleged link between the drug and pancreatic disease and cancer.
As early as September of 2009 the FDA began requiring Merck to provide warnings to consumers regarding the potential risks of Januvia and its association to pancreatic ailments. Unfortunately, Merck’s failure to provide proper warnings regarding the connection may have devastating effects on consumers taking the drug. Researchers have found that early detection is key when it comes to pancreatitis turning into cancer, however Merck’s failure to warn early on may have increased the risk to many consumers taking Januvia drug.
Many lawsuits have been filed nationwide regarding Merck’s failure to warn of Januvia’s side effects and its link to pancreatitis and pancreatic cancer. If you or someone you know has suffered from pancreatic ailments after taking Januvia you should contact an experienced attorney that will represent your rights and assist you in getting just compensation.
For assistance with your Januvia case, click here to find Januvia attorneys near you or find attorneys in a different state.